A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women

计划入组 40 人 · 首次发布于 2008 年 7 月 3 日

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers

计划入组 48 人 · 首次发布于 2008 年 9 月 19 日

Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

计划入组 11 人 · 首次发布于 2010 年 11 月 11 日

ActRIIB-2.12

ActRIIB-ALK4 Antagonist(Acceleron Pharma)

Ramatercept

Antria, Inc.

United States

Astria Therapeutics Inc

United States

ACTIV SURGICAL

India

Supercede Therapeutics Reports Promising Preclinical Data for Novel Oral Obesity Treatment Targeting ACTRII Pathway

Laekna's LAE102 Shows Promising Safety Profile in First-in-Human Obesity Trial at ADA 2025

AliveGen's ALG-801 Demonstrates Superior Efficacy Over Standard PAH Therapies in Preclinical Studies